Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13001686 | 0.82 | TSHR (0.52) | AREGLN2CYP11B1CYP11B2TSHR | |
| SCHEMBL2788786 | 0.80 | CYP11B2 (0.50) | ESR2ESR1CYP11B1CYP11B2 | |
| SCHEMBL19314123 | 0.80 | HSD17B1 (0.55) | ESR2ESR1ARHSD17B1HSD17B2 | |
| SCHEMBL2785589 | 0.79 | AR (0.57) | ESR2ESR1AREGLN2HSD17B1 | |
| SCHEMBL19880348 | 0.75 | APP (0.55) | ESR2HSD17B1HSD17B2MCL1 | |
| SCHEMBL2785702 | 0.75 | MMP3 (0.55) | ESR2ESR1ARCYP11B2MAOA | |
| SCHEMBL8338719 | 0.74 | AR (0.61) | AREGLN2CYP11B1CYP11B2MAOA | |
| SCHEMBL26391841 | 0.74 | AR (0.61) | AREGLN2CYP11B1CYP11B2MAOA | |
| SCHEMBL2785232 | 0.73 | TTR (0.41) | ESR2ESR1AREGLN2CYP11B1 | |
| SCHEMBL21899532 | 0.73 | KIF11 (0.47) | AREGLN2CYP11B1CYP11B2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258694-A1 | Amines as histamine-3 receptor ligands and their therapeutic applications | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7538138-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| US-6969730-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | disclosed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH2 | ESR2 1688/4885ESR1 2006/4885AR 3577/4885 |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | ESR2 2003/4885ESR1 2109/4885AR 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.